What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2021-05-11 compared with 2020-11-09 · 36 added, 13 removed, 16 unchanged (75% of the section changed)

Other Information

Commercial Alliance Agreement between Eyepoint Pharmaceuticals, Inc.

and ImprimisRx, LLC dated August 1, 2020.

Pharmaceuticals MAY-66 License Termination

May 10, 2021, Mayfield terminated the License Agreement (the “TGV License”) with TGV-Health, LLC and affiliated entities

(collectively, “TGV”), pursuant to which it acquired intellectual property rights for use in the women’s health field,

related to Mayfield’s proprietary drug candidate MAY-66.

Concurrent with the termination, TGV returned to Mayfield 300,000 shares

of Mayfield’s common stock, constituting all of the equity held by TGV.

Mayfield has no outstanding or remaining obligations under

the TGV License.

Pharmaceuticals MAY-44 APA Termination

May 10, 2021, Mayfield and Harrow terminated their asset purchase agreement dated January 2020 for intellectual property rights

associated with Mayfield’s drug candidate MAY-44 with Elle Pharmaceutical LLC (the “MAY-44 APA”).

the termination, Mayfield re-acquired 350,000 shares of its common stock from Elle for $350.

Mayfield has no outstanding

or remaining obligations related to the MAY-44 APA.

License Termination

May 10, 2021, Stowe terminated the License Agreement (the “Stowe License”) with TGV, pursuant to which it acquired intellectual

property rights for use in the ophthalmic field, related to Stowe’s proprietary drug candidate STE-006.

Concurrent with the termination,

TGV returned to Stowe 1,750,000 shares of Stowe’s common stock, constituting all of the equity held by TGV.

Stowe has no outstanding

or remaining obligations under the Stowe License.

Certificate of Designation designating the Series B Cumulative Preferred Stock of the Company (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Company filed with the SEC on May 5, 2021).

Indenture, dated as of April 20, 2021, by and between the Company and U.S.

Bank National Association, as Trustee (incorporated herein by reference to Exhibit 4.1 to the Current Report on Form 8-K of the Company filed with the SEC on April 20, 2021).

First Supplemental Indenture, dated as of April 20, 2021, by and between the Company and U.S.

Bank National Association, as Trustee (incorporated herein by reference to Exhibit 4.2 to the Current Report on Form 8-K of the Company filed with the SEC on April 20, 2021).

Form of 8.625% Senior Note due 2026 (included in Exhibit 4.2).

Securities Purchase Agreement, dated as of May 5, 2021, by and between the Company and B.

Riley Securities, Inc.

(incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company filed with the SEC on May 5, 2021).

Certification of Mark L.

6 unchanged sentences

Boll, principal financial and accounting officer.

XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded

within the Inline XBRL document.

XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within

the Inline XBRL document.

XBRL Taxonomy Extension Schema Document

3 unchanged sentences

XBRL Taxonomy Extension Presentation Linkbase Document

cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, has been formatted

in Inline XBRL.

Portions of this exhibit have been omitted in compliance with item

601 of Regulation S-K

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf

by the undersigned, thereunto duly authorized.

November 9, 2020

cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, has been formatted in Inline

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned, thereunto duly authorized.

Executive Officer and Director

Executive Officer)

Financial Officer

(Principal Financial and Accounting Officer)

Financial Officer (Principal Financial and Accounting Officer)

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information